Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.

Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, Viccica G, Pinchera A, Marcocci C.

J Endocrinol Invest. 2012 Jul;35(7):655-60. doi: 10.3275/7970. Epub 2011 Sep 30.

PMID:
21971564
2.

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.

Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2011 Jan;96(1):E9-18. doi: 10.1210/jc.2010-1221. Epub 2010 Oct 13.

3.

Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.

Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, Frasoldati A, Papini E, Scillitani A, Banti C, Del Prete M, Vescini F, Gianotti L, Cavalli L, Romagnoli E, Colao A, Cetani F, Marcocci C.

Clin Endocrinol (Oxf). 2013 Jul;79(1):20-6. doi: 10.1111/cen.12108. Epub 2013 Apr 27.

PMID:
23228121
4.

MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.

Filopanti M, Verga U, Ermetici F, Olgiati L, Eller-Vainicher C, Corbetta S, Persani L, Beck-Peccoz P, Spada A.

Eur J Endocrinol. 2012 Aug;167(2):157-64. doi: 10.1530/EJE-12-0117. Epub 2012 May 10.

5.

Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.

Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M.

Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30.

6.

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M.

J Clin Endocrinol Metab. 2009 Aug;94(8):2766-72. doi: 10.1210/jc.2008-2640. Epub 2009 May 26.

7.

[Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].

Arranz Martín A, Azcárate Villalón A, Luque Ramírez M, Santana Durán B, Marazuela Azpíroz M, Paniagua Ruiz A, Carraro R, Gómez Pan A.

Endocrinol Nutr. 2011 Jan;58(1):24-31. doi: 10.1016/j.endonu.2010.09.009. Spanish.

PMID:
21277266
8.

Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A.

Minerva Endocrinol. 2013 Dec;38(4):389-94.

PMID:
24285106
9.

Update on the use of cinacalcet in the management of primary hyperparathyroidism.

Marcocci C, Cetani F.

J Endocrinol Invest. 2012 Jan;35(1):90-5. doi: 10.3275/8112. Epub 2011 Nov 21. Review.

PMID:
22104762
10.

Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.

Faggiano A, Di Somma C, Ramundo V, Severino R, Vuolo L, Coppola A, Panico F, Savastano S, Lombardi G, Colao A, Gasperi M.

Endocrine. 2011 Jun;39(3):283-7. doi: 10.1007/s12020-011-9459-0. Epub 2011 Mar 29.

PMID:
21445714
11.

Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.

Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D.

J Clin Endocrinol Metab. 2009 Dec;94(12):4860-7. doi: 10.1210/jc.2009-1472. Epub 2009 Oct 16.

PMID:
19837909
12.

Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.

Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP.

J Clin Endocrinol Metab. 2007 Oct;92(10):3803-8. Epub 2007 Jul 31.

PMID:
17666472
13.

Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).

Giusti F, Cianferotti L, Gronchi G, Cioppi F, Masi L, Faggiano A, Colao A, Ferolla P, Brandi ML.

Endocrine. 2016 Jun;52(3):495-506. doi: 10.1007/s12020-015-0696-5. Epub 2015 Jul 30.

PMID:
26224587
14.

Cinacalcet for the treatment of primary hyperparathyroidism.

Sajid-Crockett S, Singer FR, Hershman JM.

Metabolism. 2008 Apr;57(4):517-21. doi: 10.1016/j.metabol.2007.11.014.

PMID:
18328354
15.

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.

Iglesias P, Ais G, González A, Tajada P, García Arévalo C, Fernández Pardo E, Díez JJ.

Am J Med Sci. 2008 Feb;335(2):111-4. doi: 10.1097/MAJ.0b013e3181379f3e.

PMID:
18277118
16.

Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Duntas LH, Stathatos N.

Endocrine. 2011 Jun;39(3):199-204. doi: 10.1007/s12020-011-9452-7. Epub 2011 Mar 26. Review.

PMID:
21442382
17.

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M, Payer J, Van De Ven A, Yavropoulou M, Selby P.

Eur J Endocrinol. 2014 Dec;171(6):727-35. doi: 10.1530/EJE-14-0355. Epub 2014 Sep 20.

18.

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D.

J Clin Endocrinol Metab. 2005 Jan;90(1):135-41. Epub 2004 Nov 2.

PMID:
15522938
19.

Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.

Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.

Nephrol Dial Transplant. 2007 Jun;22(6):1639-44. Epub 2007 Feb 3.

PMID:
17277339
20.

Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.

Norman J, Lopez J, Politz D.

Ann Surg Oncol. 2012 May;19(5):1466-71. doi: 10.1245/s10434-011-2065-9. Epub 2011 Sep 16.

PMID:
21922336

Supplemental Content

Support Center